Zeria Pharmaceutical Lifts FY2027 Forecast on Forex Recovery and Margin Expansion

Zeria Pharmaceutical Co., Ltd. (TSE:4559), a mid-sized Japanese pharmaceutical manufacturer specializing in gastrointestinal treatments and consumer wellness products, reported full-year FY2026 (ended March 2026) revenue of JPY 89.2bn, up 2.1% year-over-year, with operating profit of JPY 12.4bn (+1.4% YoY). However, ordinary income (keijo rieki, Japan’s recurring profit metric including non-operating items) fell 14.0% to JPY 11.0bn, and net profit declined 14.9% to JPY 8.45bn—declines driven primarily by foreign exchange headwinds rather than operational deterioration. Management projects a significant rebound in FY2027, forecasting revenue of JPY 95.0bn (+6.6% YoY) and net profit of JPY 10.0bn (+18.3% YoY), signaling confidence in both operational momentum and a reversal of currency losses.

Business Overview

Zeria Pharmaceutical is a mid-cap pharmaceutical company with a diversified portfolio anchored by gastrointestinal and digestive treatments, complemented by established over-the-counter (OTC) wellness brands such as Heparize (a liver-support tonic). The company has pursued aggressive international expansion, with overseas revenue rising to 59.3% of total sales from 56.9% in the prior year, reflecting a strategic pivot toward global markets while maintaining profitability in its domestic base.

Results Analysis: Operational Strength Masked by Currency Headwinds

The headline profit declines mask a more nuanced operational picture. Operating profit grew 1.4% despite a modest 2.1% revenue increase, demonstrating that Zeria’s core business remains resilient even as cost pressures—typical across the pharmaceutical sector—compress margins. The 13.9% operating margin substantially exceeds typical pharmaceutical industry levels, underscoring the company’s competitive positioning and pricing power in its core therapeutic areas.

The sharp 14.0% decline in ordinary income and 14.9% drop in net profit reflects a critical structural shift: foreign exchange losses. In the prior year, Zeria benefited from favorable forex movements; in FY2026, the company recorded substantial currency losses as the yen strengthened against major trading currencies. With nearly 60% of revenue now denominated in foreign currencies, this exposure is material. Critically, this is a non-operational headwind—the business itself is performing adequately.

Zeria strengthened its balance sheet materially, with the equity ratio rising 400 basis points to 60.3%, reflecting accumulated retained earnings and a disciplined capital allocation strategy that included JPY 3.0bn in share buybacks during the period. Net assets (jiko shihon) expanded to JPY 108.6bn from JPY 89.8bn, a 20.9% increase, while book value per share rose to JPY 2,459.12 from JPY 2,031.33, demonstrating tangible shareholder value creation despite headline profit declines.

Next Year Guidance

Management’s FY2027 guidance is notably ambitious, particularly for ordinary income and net profit, which are projected to grow in the high-teens percentage range. This implies a sharp reversal of forex losses—management is implicitly forecasting either a weaker yen or reduced currency headwinds. The ordinary income target of JPY 13.0bn (matching operating profit guidance) suggests near-elimination of non-operating losses. Revenue growth of 6.6% substantially outpaces FY2026’s 2.1%, indicating accelerating top-line momentum, likely from international expansion and new product contributions. Operating profit growth of 5.1% lags revenue growth, implying modest margin compression from mix or investment, but the absolute margin level should remain robust.

What to Watch

Forex Sensitivity and Yen Dynamics: With 59.3% of revenue now international, currency movements will remain the primary driver of ordinary income volatility. Investors should monitor Bank of Japan policy signals and USD/JPY levels closely; a sustained yen weakness would validate management’s FY2027 guidance, while further appreciation could pressure results.

Margin Trajectory in Gastrointestinal Segment: Operating profit growth (5.1%) trailing revenue growth (6.6%) warrants attention. Pharmaceutical input costs and manufacturing pressures are evident; management must demonstrate that pricing discipline and operational efficiency can stabilize margins above the 13% level.

International Expansion Execution: The shift toward overseas revenue (now 59.3%) is strategic but carries execution risk. Investors should track geographic segment performance, particularly in Asia and emerging markets, to assess whether international growth is sustainable and profitable.

Source: Original filing (TDnet) | 日本語版

This article is for informational purposes only and does not constitute investment advice. Financial figures are AI-extracted and may contain errors — always verify against the original filing.